Preclinical Overview of Sorafenib, a Multikinase Inhibitor That Targets Both Raf and VEGF and PDGF Receptor Tyrosine Kinase Signaling
Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-08-0013
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2008
Authors
Publisher
American Association for Cancer Research (AACR)